Optimal amyloid and tau CSF biomarkers for the detection of amyloid and tau PET positivity in a memory clinic population
Rattachement africain : ch, us, it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Accurate detection of Alzheimer’s disease (AD) pathophysiological changes is crucial for research and clinical practice. While positron emission tomography (PET) imaging is an established reference standard for detecting brain amyloid and tau deposition, cerebrospinal fluid (CSF) biomarkers offer a more accessible alternative. This study aimed to identify optimal CSF biomarkers and thresholds for predicting tau and amyloid PET positivity in a memory clinic population. Methods This cross-sectional, observational study included 220 participants from a memory clinic who underwent amyloid or tau PET scans and CSF biomarker analysis using either Fujirebio INNOTEST or LUMIPULSE assays. CSF biomarker performance was assessed via receiver operating characteristic (ROC) analysis. Double-threshold approaches were implemented to address classification uncertainty. Results Ratios combining biomarkers of both amyloid and tau, such as Aβ42/pTau, consistently outperformed individual biomarkers in detecting amyloid and tau PET positivity. For amyloid PET, the Aβ42/pTau ratio achieved an AUC of 0.93 (95% CI: 0.86–0.99) with INNOTEST and an AUC of 0.89 (95% CI: 0.8–0.98) with LUMIPULSE. For tau PET, the Aβ42/pTau ratio achieved an AUC of 0.85 (95% CI: 0.77–0.93) with INNOTEST and an AUC of 0.97 (95% CI: 0.9-1.00) with LUMIPULSE. Double thresholds enabled classification based on predefined sensitivity and specificity, and can be used by clinicians to quickly assess a subject’s likelihood of positivity based on their biomarker levels. Discussion CSF biomarker ratios such as Aβ42/pTau provide high predictive accuracy for brain amyloid and tau deposition. Implementing double thresholds enhances clinical utility by highlighting ambiguous cases requiring further assessment.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Optimal amyloid and tau CSF biomarkers for the detection of amyloid and tau PET positivity in a memory clinic population
- Date Crossref
- 14/08/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.